Saga Diagnostics is at the forefront of advancing cancer diagnostics through its proprietary Molecular Residual Disease (MRD) testing platform. This innovative technology combines next-generation sequencing (NGS) with novel digital PCR (dPCR) methods to create a unique tumor-informed MRD approach. By tracking patient-specific structural variants (SVs), the platform enables the early and accurate detection of residual disease following curative intent therapy. The process begins with low-depth whole genome sequencing of tumor samples, which identifies a personalized genetic fingerprint of up to 16 somatic SVs. This fingerprint is then orthogonally validated through digital PCR analyses of both blood and tumor DNA, allowing for precise monitoring of a patient's cancer status through simple blood draws.

The MRD testing platform developed by Saga Diagnostics is designed to provide timely and actionable insights for patients, oncologists, and biopharma partners. With its ultra-sensitive and specific assays, the technology facilitates the assessment of post-interventional residual disease, early signs of recurrence, and therapeutic response across various stages of cancer. This capability not only enhances patient care by enabling continuous monitoring but also supports biopharma companies in drug development and clinical trials by providing reliable data for biomarker discovery and patient stratification. Overall, Saga Diagnostics' approach represents a significant leap forward in the precision of cancer diagnostics, offering hope for improved outcomes in cancer therapy decision-making.

Sweden

SAGA Diagnostics is a personalised cancer medicine and disease monitoring company focused on molecular genetic analyses of circulating tumor DNA and tissue biopsies.

Saga Diagnostics

Company Details